Theophylline has been relegated to a second-or even third-line therapy in the treatment of
asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids …

Rationale: The oral phosphodiesterase-4 (PDE4) inhibitor, roflumilast, can improve lung
function in moderate chronic obstructive pulmonary disease (COPD). Whether treatment is …

Chronic obstructive pulmonary disease is characterized by a rapid decline in lung function
due to small airway fibrosis, mucus hypersecretion and emphysema. The major causative …

The dose‐proportional, intraindividual, single‐and repeated‐dose pharmacokinetics of
roflumilast, an oral, once‐daily phosphodiesterase 4 inhibitor under investigation for chronic …

Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a
progressive disease characterized by inflammation and predominantly caused by tobacco …

Chronic obstructive pulmonary disease (COPD) is a global health problem. COPD is
associated with the progressive pulmonary inflammation and destruction of lung …

Chronic obstructive pulmonary disease represents a major global health care burden for
both primary and secondary care providers and is the most common respiratory condition …

During the past ten years, the pharmaceutical industry has focussed on treating chronic
obstructive pulmonary disease (COPD) as distinct to asthma, and no novel anti-inflammatory …

Long-acting bronchodilator therapy should be considered when a COPD patient is
symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy …

What is already known about this subject• Cytochrome P450 (CYP) 3A4 plays a prominent
role in the metabolism of many drugs, which in turn implies, that changes in the activity of …